Acid-C2-PEG4-C2-NHS ester

Cat. No.: HY-130436

CAS No.: 1343476-41-4

Molecular Formula: $C_{18}H_{29}NO_{11}$

Molecular Weight: 435.42

Target: PROTAC Linkers

Pathway: PROTAC

Storage:

Pure form	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (229.66 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2966 mL	11.4832 mL	22.9663 mL
	5 mM	0.4593 mL	2.2966 mL	4.5933 mL
	10 mM	0.2297 mL	1.1483 mL	2.2966 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Acid-C2-PEG4-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC_{50} & Target		
	PEGs	Alkyl/ether

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA